Alnylam Pharmaceuticals, Inc. has announced the promotion of Pushkal Garg, M.D., to the position of Executive Vice President and Chief Research and Development Officer. The company is focusing on delivering RNA interference (RNAi) therapeutics to all major tissues by 2030. This strategic move comes as the company aims to accelerate pipeline progress by fostering earlier collaboration, faster decision-making, and more agile responses to scientific opportunity and patient need.
Alnylam has made considerable progress across all facets of its innovation engine, achieving numerous drug approvals and positive Phase 3 readouts. The company has rapidly increased the size of its clinical pipeline, demonstrating significant growth. The appointment of Dr. Garg to lead the combined research and development organization underscores the company's commitment to scaling its impact and transforming the lives of patients across a growing number of diseases.
Dr. Garg, who joined Alnylam in 2014, brings strategic vision, operational excellence, and an impressive track record in building and steering an industry-leading, innovative drug development organization. He holds a B.A. with high honors in biochemistry from the University of California, Berkeley, and an M.D. from the University of California, San Francisco. Dr. Garg completed residency training in internal medicine at UCSF, was a fellow in the Robert Wood Johnson Clinical Scholars program at Johns Hopkins University, and served on the faculty of Harvard Medical School and the Brigham & Women’s Hospital in Boston prior to joining the industry.
RNAi therapeutics, a natural cellular process of gene silencing, has been recognized as a major scientific breakthrough. By harnessing the natural biological process of RNAi occurring in our cells, a new class of medicines known as RNAi therapeutics has become a reality. Alnylam's RNAi therapeutic platform, comprising small interfering RNA (siRNA) molecules, functions upstream of today's medicines by potently silencing messenger RNA (mRNA), which encode disease-causing or disease pathway proteins, thus preventing them from being made.
Since its founding in 2002, Alnylam has led the translation of RNAi into a new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet needs. The company has a deep pipeline of investigational medicines, including multiple product candidates in late-stage development. Alnylam's "Alnylam P5x25" strategy aims to deliver transformative medicines in both rare and common diseases, benefiting patients worldwide through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile.
Alnylam's headquarters is located in Cambridge, MA. As a result of these announcements, the company's shares have moved 1.17% on the market, and are now trading at a price of $312.32. Check out the company's full 8-K submission here.
